Xenetic Biosciences - XBIO

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by Dan Thunderbolt, Jul 13, 2020.

  1. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    737
    Likes Received:
    77
    Bought a first position here. I like the risk/reward ratio…

    Price: $1.02
    Market Cap: ~ $6.4 Million
    Shares Outstanding: ~ 6.3 Million
    Cash balance (as of March 31, 2020): ~ $9.4 Million
    Cash expected to fund through mid 2021

    Lead product: XCART™ (Preclinical, see slide 24 for possible value of CAR T therapeutics acquisitions with lead program in preclinical development)

    Company presentation July 2020
    https://ir.xeneticbio.com/presentations

    [​IMG]

    [​IMG]
     
  2. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    737
    Likes Received:
    77
    The stock ended yesterday at $1.24

    Market Cap is still below cash.
     
  3. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    737
    Likes Received:
    77
    Sold my shares today with 50 % gain. I will consider buying again at lower levels...
     
  4. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    737
    Likes Received:
    77
    Xenetic Biosciences, Inc. Announces Positive Data from Partner’s Pivotal Phase 3 Clinical Trial Utilizing PolyXen(R) Platform Technology
    Wed, December 9, 2020, 2:35 PM GMT
    • Xenetic leverages its proprietary drug delivery platform, PolyXen, through partnerships with biotechnology and pharmaceutical companies to improve the half-life and other pharmacological properties of next-generation biologic drugs

    • Epolong, a polysialylated form of recombinant human erythropoietin that leverages PolyXen, has been shown to be effective and generally well tolerated in Pharmsynthez-conducted trial as a treatment for anemia in patients with chronic kidney disease
     

Share This Page